[go: up one dir, main page]

NO20021625L - Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog - Google Patents

Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog

Info

Publication number
NO20021625L
NO20021625L NO20021625A NO20021625A NO20021625L NO 20021625 L NO20021625 L NO 20021625L NO 20021625 A NO20021625 A NO 20021625A NO 20021625 A NO20021625 A NO 20021625A NO 20021625 L NO20021625 L NO 20021625L
Authority
NO
Norway
Prior art keywords
receptor antagonist
synergistic combinations
gaba
structural analogue
gaba structural
Prior art date
Application number
NO20021625A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021625D0 (no
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20021625D0 publication Critical patent/NO20021625D0/no
Publication of NO20021625L publication Critical patent/NO20021625L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20021625A 1999-10-07 2002-04-05 Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog NO20021625L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (2)

Publication Number Publication Date
NO20021625D0 NO20021625D0 (no) 2002-04-05
NO20021625L true NO20021625L (no) 2002-04-05

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021625A NO20021625L (no) 1999-10-07 2002-04-05 Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (tr)
JP (2) JP2003510356A (tr)
KR (1) KR20020060192A (tr)
CN (1) CN1387434A (tr)
AP (1) AP2002002501A0 (tr)
AR (1) AR029646A1 (tr)
AT (1) ATE269072T1 (tr)
AU (2) AU7663300A (tr)
BG (1) BG106548A (tr)
BR (1) BR0014598A (tr)
CA (1) CA2385930A1 (tr)
CO (1) CO5280195A1 (tr)
CR (1) CR6614A (tr)
CZ (1) CZ20021116A3 (tr)
DE (1) DE60011650T2 (tr)
DK (1) DK1221950T3 (tr)
EA (1) EA004266B1 (tr)
EE (1) EE200200185A (tr)
ES (1) ES2220542T3 (tr)
GT (1) GT200000166A (tr)
HR (1) HRP20020286A2 (tr)
HU (1) HUP0203466A3 (tr)
IL (1) IL148965A0 (tr)
IS (1) IS6318A (tr)
MA (1) MA26826A1 (tr)
MX (1) MXPA02003484A (tr)
NO (1) NO20021625L (tr)
NZ (1) NZ517949A (tr)
OA (1) OA12063A (tr)
PA (1) PA8504301A1 (tr)
PE (1) PE20010708A1 (tr)
PL (1) PL357498A1 (tr)
PT (1) PT1221950E (tr)
SK (1) SK4542002A3 (tr)
TR (1) TR200200913T2 (tr)
UY (1) UY26376A1 (tr)
WO (2) WO2001024792A1 (tr)
ZA (1) ZA200202675B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
CN113631150A (zh) * 2019-03-26 2021-11-09 奥赖恩公司 普瑞巴林制剂及其用途
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
EP0929303B1 (en) * 1996-10-07 2006-07-26 Merck Sharp & Dohme Ltd. Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
NO20021625D0 (no) 2002-04-05
TR200200913T2 (tr) 2002-09-23
IS6318A (is) 2002-03-21
EP1221950B1 (en) 2004-06-16
HRP20020286A2 (en) 2003-08-31
CR6614A (es) 2003-12-04
OA12063A (en) 2006-05-03
EA004266B1 (ru) 2004-02-26
JP2003510355A (ja) 2003-03-18
NZ517949A (en) 2003-08-29
WO2001024791A1 (en) 2001-04-12
JP2003510356A (ja) 2003-03-18
HUP0203466A3 (en) 2005-03-29
AR029646A1 (es) 2003-07-10
WO2001024792A9 (en) 2002-09-06
KR20020060192A (ko) 2002-07-16
CA2385930A1 (en) 2001-04-12
PE20010708A1 (es) 2001-07-27
DE60011650D1 (de) 2004-07-22
EA200200303A1 (ru) 2002-08-29
EE200200185A (et) 2003-04-15
EP1233766A1 (en) 2002-08-28
MA26826A1 (fr) 2004-12-20
ES2220542T3 (es) 2004-12-16
AU7663300A (en) 2001-05-10
GT200000166A (es) 2002-03-30
BR0014598A (pt) 2002-06-11
AU1696201A (en) 2001-05-10
SK4542002A3 (en) 2003-09-11
ATE269072T1 (de) 2004-07-15
BG106548A (en) 2002-12-29
HUP0203466A2 (hu) 2003-02-28
DE60011650T2 (de) 2005-07-14
MXPA02003484A (es) 2004-09-10
CZ20021116A3 (cs) 2003-05-14
ZA200202675B (en) 2003-04-15
CO5280195A1 (es) 2003-05-30
EP1221950A1 (en) 2002-07-17
AP2002002501A0 (en) 2002-06-30
UY26376A1 (es) 2000-12-29
PT1221950E (pt) 2004-08-31
IL148965A0 (en) 2002-11-10
PL357498A1 (en) 2004-07-26
PA8504301A1 (es) 2002-08-26
DK1221950T3 (da) 2004-09-20
CN1387434A (zh) 2002-12-25
WO2001024792A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE418986T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
IS8807A (is) Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
NO20021625L (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
EP0657167A3 (fr) Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum.
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
IL101441A0 (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
DK0942729T3 (da) Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application